In the same way, Schoenfeld and collaborators, in a large cohort of lung adenocarcinoma, found that alterations in KRAS and MET were significantly associated with high expression of PD-L1, whereas EGFR mutations were associated with low PD-L1 levels. The gene discussed is EGFR; the disease is lung adenocarcinoma.